NASDAQ:ESRX - Express Scripts Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$87.85 -0.15 (-0.17 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$88.00
Today's Range$87.68 - $88.13
52-Week Range$55.80 - $88.30
Volume5.30 million shs
Average Volume4.36 million shs
Market Capitalization$49.13 billion
P/E Ratio12.37
Dividend YieldN/A
Beta0.95
Express Scripts logoExpress Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Debt-to-Equity Ratio0.69
Current Ratio0.71
Quick Ratio0.59

Price-To-Earnings

Trailing P/E Ratio12.37
Forward P/E Ratio9.69
P/E Growth1.1

Sales & Book Value

Annual Sales$100.06 billion
Price / Sales0.49
Cash Flow$10.5462 per share
Price / Cash8.33
Book Value$32.00 per share
Price / Book2.75

Profitability

EPS (Most Recent Fiscal Year)$7.10
Net Income$4.52 billion
Net Margins4.65%
Return on Equity25.49%
Return on Assets8.58%

Miscellaneous

Employees26,600
Outstanding Shares562,230,000
Market Cap$49.13 billion

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts announced that its Board of Directors has initiated a share buyback program on Wednesday, December 20th 2017, which allows the company to repurchase 45,000,000 shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its stock is undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts Holding Co (NASDAQ:ESRX) issued its quarterly earnings data on Wednesday, August, 1st. The company reported $2.22 EPS for the quarter, topping analysts' consensus estimates of $2.20 by $0.02. The firm earned $25.64 billion during the quarter, compared to analyst estimates of $25.43 billion. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. Express Scripts's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.73 earnings per share. View Express Scripts' Earnings History.

When is Express Scripts' next earnings date?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts updated its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of $9.00-9.14 for the period, compared to the Thomson Reuters consensus estimate of $9.05. The company issued revenue guidance of $99-102 billion, compared to the consensus revenue estimate of $100.99 billion.

What price target have analysts set for ESRX?

17 equities research analysts have issued 12-month price targets for Express Scripts' stock. Their forecasts range from $68.00 to $101.00. On average, they expect Express Scripts' share price to reach $83.5417 in the next twelve months. This suggests that the stock has a possible downside of 4.9%. View Analyst Price Targets for Express Scripts.

What is the consensus analysts' recommendation for Express Scripts?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 2 sell ratings, 11 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:
  • 1. According to Zacks Investment Research, "Express Scripts currently faces persistent drug pricing issue, which is anticipated to affect the stock. A lackluster guidance for 2018 also raises concern. Moreover, the company faces stiff competition in niche space. Express Scripts announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with the company anymore. Furthermore, the company is getting acquired by Cigna Corporation. However, the company has been benefitting from a rise in patient claims and strong customer retention. Express Scripts' PBM segment coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. Furthermore, recent collaborations also deserve mention. Notably, management expects cumulative savings of nearly $1.2 billion by 2021. Express Scripts outperformed its industry in past year." (7/23/2018)
  • 2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)

Are investors shorting Express Scripts?

Express Scripts saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 15,264,183 shares, an increase of 16.5% from the July 13th total of 13,104,769 shares. Based on an average daily trading volume, of 3,184,234 shares, the days-to-cover ratio is presently 4.8 days. Currently, 2.7% of the shares of the company are short sold. View Express Scripts' Current Options Chain.

Who are some of Express Scripts' key competitors?

Who are Express Scripts' key executives?

Express Scripts' management team includes the folowing people:
  • Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
  • Mr. James M. Havel, Exec. VP & CFO (Age 63)
  • Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
  • Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
  • Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)

Has Express Scripts been receiving favorable news coverage?

Press coverage about ESRX stock has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Express Scripts earned a news impact score of 0.20 on Accern's scale. They also gave news stories about the company an impact score of 46.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Express Scripts.

Who are Express Scripts' major shareholders?

Express Scripts' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.30%), Macquarie Group Ltd. (1.64%), Massachusetts Financial Services Co. MA (1.23%), Bank of New York Mellon Corp (1.22%), Dimensional Fund Advisors LP (1.15%) and LSV Asset Management (0.90%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Which institutional investors are selling Express Scripts stock?

ESRX stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Russell Investments Group Ltd., Los Angeles Capital Management & Equity Research Inc., Schroder Investment Management Group, Morgan Stanley, Millennium Management LLC, Meadow Creek Investment Management LLC and Macquarie Group Ltd.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Which institutional investors are buying Express Scripts stock?

ESRX stock was purchased by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Canada Pension Plan Investment Board, FMR LLC, Bank of Montreal Can, BlackRock Inc., Korea Investment CORP, Chevy Chase Trust Holdings Inc. and IndexIQ Advisors LLC. View Insider Buying and Selling for Express Scripts.

How do I buy shares of Express Scripts?

Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of ESRX stock can currently be purchased for approximately $87.85.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $49.13 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  741 (Vote Outperform)
Underperform Votes:  530 (Vote Underperform)
Total Votes:  1,271
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel